PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 6: WO 99/36076 (11) International Publication Number: A61K 33/24, 31/675, 31/505, 31/70, 31/13 A1 (43) International Publication Date: 22 July 1999 (22.07.99) (74) Agent: BERESKIN & PARR; 40th floor, 40 King Street West, PCT/QA99/00005 (21) International Application Number: Toronto, Ontario M5H 3Y2 (CA). (22) International Filing Date: 13 January 1999 (13.01.99) (30) Priority Data: 13 January 1998 (13.01.98) 60/071,023 (71) Applicant (for all designated States except US): UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. [CA/CA]; 117 Science Place, Saskatoon, Saskatchewan S7N 5C8 TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, (CA). (71) Applicant (for US only): THE CANADA TRUST COMPANY (executor for the deceased invantor) [GB/CA], Suite 800, SN, TD, TG). 421 7th Avenue, Calgary, Alberta T2P 3Y8 (CA). Published (72) Inventor: PATERSON, I., Alick (deceased). With international search report. Before the expiration of the time limit for amending the (72) Inventors; and (75) Inventors/Applicants (for US only): WARRINGTON, R., C. claims and to be republished in the event of the receipt of [CACA]; University of Saskatchewan, Neuropsychiatry Research Unit A, 114 Medical Research Building, 103 Ü amendments. Wiggins Road, Saskatoon, Saskatchewan S7N 5E4 (CA). BOULTON, Alan, A. [CA/CA]; 1905 Spadina Crescent lat. East, Saskatoon, Saskatchewan S7K 0C9 (CA). H M (54) Title: COMPOSITION CONTAINING PROPARGY LAMINE FOR ENHANCING CANCER THERAPY. (57) Abstract 4 Antineoplastic drug modulators are described. The specific modulators referred to are propargylamines which can enhance the cytotoxic jal. effects of antineoplastic drugs on cancer cells while protecting normal cells from damage. The propargylamine modulators can be used to increase the selectivity and effectiveness of conventional antineoplastic drugs, to reduce the unwanted side-effects of cancer chemotherapy, to improve effectiveness of cancer chemotherapy, to improve treatment of cancers for which treatment is otherwise ineffective, to improve therapy of cancers otherwise unresponsive or poorly responsive due to drug-resistance and/or toxicity limited treatment regimens and to render effective chemotherapy for previously untreatable cancers.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	Fl	Finland	LT	Lithuania	- SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	าบ	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	ТT	Trinidad and Tobago
BJ	Benin	1E	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	1L	· Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	ΙT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CC	Congo	KB	Kenya	NL .	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
СМ	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		